| abstract |
The present invention relates to peptide dimer compounds and peptide monomer compounds, which effectively inhibit in vivo α4β7 binding to mucosal addressin cell adhesion molecule (MAdCAM), have high selectivity for α4β1 binding, and have high stability under gastrointestinal conditions . The present application was developed in response to the problems and needs in the art that have not been adequately addressed by currently available integrin antagonists in the prior art. |